US EditionPublished • loading... • Updated
New Published Case Series Explores Umbilical Cord Tissue Allografts in Plantar Fascia Care
Nine patients with plantar fasciopathy showed a 61% pain reduction and 50% functional improvement after a single Wharton's jelly allograft, with no adverse reactions reported.
- Following peer-reviewed publication in Biomedicines, Regenative Labs announced a study published Sept. 24, 2025, reporting 90-day improvements in plantar fasciopathy outcomes.
- Described by the authors as a degenerative collagen-based condition, plantar fasciopathy involved patients who failed at least three months of conservative therapy and used Wharton's jelly, umbilical cord-derived connective tissue rich in extracellular matrix.
- The study used a single ultrasound-guided 2 cc injection of 150 mg/mL Wharton's jelly, under IRB oversight, following FDA- and AATB-aligned tissue processing protocols, in nine patients.
- Reported outcomes showed a 60.98% mean improvement in NPRS at Day 90, with no adverse reactions reported, according to the study.
- Given study limitations, authors disclosed relationships with Regenative Labs, including company involvement, and noted small sample size and absence of control group, calling for larger prospective trials.
Insights by Ground AI
25 Articles
25 Articles
LoudounTimes.com+24 Reposted by 24 other sources
New Published Case Series Explores Umbilical Cord Tissue Allografts in Plantar Fascia Care
PENSACOLA, Fla., Feb. 4, 2026 /PRNewswire/ -- Regenative Labs, in collaboration with Babak Baravarian, DPM, Director of Foot & Ankle Research at University Foot & Ankle Institute, today announced the publication of a new observational case series examining the use…
Coverage Details
Total News Sources25
Leaning Left4Leaning Right3Center6Last UpdatedBias Distribution46% Center
Bias Distribution
- 46% of the sources are Center
46% Center
L 31%
C 46%
R 23%
Factuality
To view factuality data please Upgrade to Premium
